-
-
Nearly 40 Institutions Participated in Aimei Vaccine's Investor Open Day Event
2023-12-28On December 27, Aimei Vaccine announced that it held an investor open day event on December 22. Almost 40 investment institutions, including CITIC Securities, CITIC Construction Investment Securities, Guotai Junan Securities, and CMB International Securities, visited and toured Aimei's bacterial vaccine industrialization base and mRNA and viral vaccine industrialization production base in Ningbo. They engaged in on-site visits, discussions, and exchanges, gaining detailed insight into the upcoming innovative vaccine products slated for market launch and their production workshop construction, as well as understanding the layout and development plans of the company's product pipeline.
-
-
-
Strategic Collaboration Initiated between Aimei Vaccine and China Foundation for Viral Hepatitis, Jointly Promoting the Elimination of Hepatitis Threats
2023-12-08Aimei Vaccine took a significant and important step toward "responding to the WHO's action to eliminate the threat of viral hepatitis by 2030." On December 6, Aimei Vaccine formally entered into a strategic cooperation agreement with the China Foundation for Viral Hepatitis (hereinafter referred to as "the Foundation") to jointly promote the elimination of hepatitis threats in China.
-
-
-
Nearly 40 Institutions Participated in Aimei Vaccine's Investor Open Day Event
2023-12-28 -
On December 27, Aimei Vaccine announced that it held an investor open day event on December 22. Almost 40 investment institutions, including CITIC Securities, CITIC Construction Investment Securities, Guotai Junan Securities, and CMB International Securities, visited and toured Aimei's bacterial vaccine industrialization base and mRNA and viral vaccine industrialization production base in Ningbo. They engaged in on-site visits, discussions, and exchanges, gaining detailed insight into the upcoming innovative vaccine products slated for market launch and their production workshop construction, as well as understanding the layout and development plans of the company's product pipeline.
-
-
-
Strategic Collaboration Initiated between Aimei Vaccine and China Foundation for Viral Hepatitis, Jointly Promoting the Elimination of Hepatitis Threats
2023-12-08 -
Aimei Vaccine took a significant and important step toward "responding to the WHO's action to eliminate the threat of viral hepatitis by 2030." On December 6, Aimei Vaccine formally entered into a strategic cooperation agreement with the China Foundation for Viral Hepatitis (hereinafter referred to as "the Foundation") to jointly promote the elimination of hepatitis threats in China.
-
-
-
MSCI Index Adjustment Takes Effect, Aimei Vaccine Joins MSCI Global Small Cap Index, Attracting More Diverse Investors
2023-12-01 -
In line with the November quarterly index review announced by MSCI, Aimei Vaccine (06660) was selected as a component stock of the MSCI Global Small Cap Index, with the adjustment taking effect after the market close on November 30.
-
-
-
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Reaches Its Final Stage and Will Soon Begin Statistical Unblinding
2023-10-18 -
Aimei Vaccine (06660) announced that the Phase III clinical trial of the group's 13-valent pneumococcal polysaccharide conjugate investigational vaccine started recruiting subjects at five sites, including Lincang and Dali in Yunnan in February 2022, with a total of 3780 enrolled subjects. The trial is currently in the phase of blood sample collection six months after full vaccination, with the basic immunogenicity MOPA serum testing completed to date and statistical unblinding set to begin soon.
-
-
-
Zhejiang Food and Drug Inspection Research Institute Investigated Aimei Vaccine and Highly Praises the Company's Development Speed
2023-10-11 -
On October 8th, vice president Chen Bilian, Tao Qiaofeng, director of the Biological Products Institute, Zhou Minghao, key personnel He Kailun, and Shao Jiamei from the Zhejiang Food and Drug Inspection Research Institute visited Aimei Vaccine's subsidiaries Aimei Rong'an and Aimei Weixin for investigation, research, and guidance. Zhu Nan, general manager of Aimei Weixin, and Hu Dedong, deputy general manager of Aimei Rong'an, led the team to welcome the experts from the Zhejiang Provincial Drug Inspection Institute, expressing sincere gratitude on behalf of the group's senior management.
-
-
-
Aimei Vaccine (06660) Initiates A-share Listing Plan, Leading Vaccine Company Embarks on A+H Strategic Layout
2023-10-09 -
Aimei Vaccine (06660) announced its decision to initiate the plan for the first public offering of RMB ordinary shares and listing (A-share listing) to promote business development, enhance comprehensive competitiveness, and ensure the realization of the company's operational goals and future development strategies. The board of directors has approved the related work for the A-share listing.
-
-
-
Aimei Vaccine (06660) Achieves Good Results in Phase III Clinical Trial of Rabies Vaccine without Serum
2023-09-20 -
Aimei Vaccine (06660) announced that its freeze-dried human rabies vaccine (serum-free Vero cell) has completed the full-course vaccination safety observation seven days after the first dose in the phase III clinical trial on September 18th, indicating good safety from the first dose to seven days after the entire course. As a product iteration upgrade, there is currently no serum-free rabies vaccine approved for marketing in the market.
-
-
-
Conference on Adult Hepatitis B Screening and Immunization Strategy Expert Seminar Participated by Aimei Vaccine in China
2023-09-09 -
The Chinese Preventive Medicine Association recently held the Conference on Adult Hepatitis B Screening and Immunization Strategy in Beijing. Aimei Vaccine, as China's largest hepatitis B vaccine manufacturer, attended the meeting as a collaborator and participated in the "Expert Consensus on Immunization Strategy for Adult Hepatitis B Vaccination in China" project.
-
-
-
Aimei Vaccine has received approval to issue domestic shares
2023-08-30 -
Aimei Vaccine(06660.HK) has received approval to issue non-publicly listed RMB common shares (i.e., domestic shares) to specific entities, according to its latest announcement on August 30.
-